Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combining rTMS With Varenicline to Prevent Smoking Lapse in Schizophrenia

NCT03497299 is registered in ClinicalTrials.gov with Centre for Addiction and Mental Health as lead sponsor.

NCT NCT03497299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03497299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combining rTMS With Varenicline to Prevent Smoking Lapse in Schizophrenia
Lead sponsor
Centre for Addiction and Mental Health
Phase
Phase 2
Overall status
Withdrawn
Start date
July 1, 2018
Completion date
August 31, 2022
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive functioning, craving, schizophrenia, tobacco use disorder